


# Representative Life Science Deals

- Over \$7.3 Billion in Commitments to more than 410 Companies since 2003
- Total New Debt & Equity Commitments of ~\$881.9 Million in 2017
- Total New Fundings of ~\$764.7 Million in 2017
- Over 1,000 Co-investments with Different VC & PE Firms in the Last 14 Years
- Over 130 Companies completed IPO or M&A Events since Inception




**\$30,000,000  
Debt Commitment**

Invested in 2011, 2013, 2015, 2017  
NASDAQ: ACRX




**\$35,000,000  
Debt Commitment**

Invested in 2017



**\$20,000,000  
Debt Commitment**

Invested in 2017  
NASDAQ: BOLD




**\$55,000,000  
Debt Commitment**

Invested in 2017  
NASDAQ: AXON




**\$30,000,000  
Debt Commitment**

Invested in 2016, 2017  
NASDAQ: BLCM




**\$25,000,000  
Debt Commitment**

Invested in 2017




**\$30,000,000  
Debt Commitment**

Invested in 2017




**\$40,000,000  
Debt Commitment**

Invested in 2017




**\$30,000,000  
Debt Commitment**

Invested in 2017



**\$15,000,000  
Debt Commitment**  
**\$1,000,000  
Equity Commitment**

Invested in 2014, 2015,  
2016, 2017



**\$20,000,000  
Debt Commitment**

Invested in 2017



**\$45,000,000  
Debt Commitment**

Invested in 2014, 2015, 2016  
NASDAQ: ALIM



\$30,000,000  
**Debt Commitment**  
 \$20,000,000  
**Prior Debt Commitment**

Invested in 2011, 2012, 2017  
 NASDAQ: CNCE



\$60,000,000  
**Debt Commitment**  
 \$1,000,000  
**Equity Commitment**

Invested in 2014, 2015, 2016, 2017  
 NASDAQ: PRTK



\$20,000,000  
**Debt Commitment**  
 \$1,000,000  
**Equity Commitment**

Invested in 2014, 2015, 2016  
 NASDAQ: EDGE



\$55,000,000  
**Debt Commitment**  
 \$1,000,000  
**Equity Commitment**

Invested in 2012, 2014, 2016  
 NASDAQ: INSM



\$60,000,000  
**Debt Commitment**

Invested in 2016  
 NASDAQ: SRNE



\$15,000,000  
**Debt Commitment**

Invested in 2014, 2015  
 Acquired by Jazz Pharma in 2016



\$40,000,000  
**Debt Commitment**  
 \$550,000  
**Equity Commitment**

Invested in 2014, 2015  
 NASDAQ: DVAX



\$15,000,000  
**Debt Commitment**  
 \$905,000  
**Equity Commitment**

Invested in 2013, 2014, 2015



\$30,000,000  
**Debt Commitment**  
 \$2,000,000  
**Prior Debt Commitment**

Invested in 2014, 2015



\$25,000,000  
**Debt Commitment**  
 \$55,000,000  
**Prior Debt Commitment**

Invested in 2005, 2007, 2012, 2015  
 NASDAQ: MACK



\$25,000,000  
**Debt Commitment**  
 \$1,500,000  
**Equity Commitment**

Invested in 2014, 2015  
 NASDAQ: NEOS



\$15,500,000  
**Debt Commitment**  
 \$500,000  
**Equity Commitment**

Invested in 2013, 2014, 2015



\$8,500,000  
**Debt Commitment**  
 \$2,500,000  
**Equity Commitment**

Invested in 2008, 2010, 2012, 2015



\$20,000,000  
**Debt Commitment**

Invested in 2013, 2014  
 NASDAQ: QURE



\$45,000,000  
**Debt Commitment**

Invested in 2013  
 Acquired by Pfizer in 2016



\$22,000,000  
**Debt Commitment**

Invested in 2011  
 NASDAQ: RVNC

## Boston Office

### R. Bryan Jadot

Sr. Managing Director  
 617.314.9981  
 bjadot@htgc.com

### Kristen Kosofsky

Sr. Managing Director  
 617.851.5416  
 kkosofsky@htgc.com

### Janice Bourque

Managing Director  
 617.314.9992  
 jbourque@htgc.com

## Palo Alto Office

### Himani Bhalla

Principal  
 650.433.5581  
 hbhalla@htgc.com

### Jeffrey Becker

Vice President  
 650.433.5595  
 jbecker@htgc.com

## San Diego Office

### Lake McGuire

Managing Director  
 517.304.0382  
 lmcguire@htgc.com

## New York Office

### Anup Arora

Managing Director  
 212.774.3612  
 aarora@htgc.com